# Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease

> **NCT07151378** · PHASE3 · RECRUITING · sponsor: **University Hospital Tuebingen** · enrollment: 150 (estimated)

## Conditions studied

- PARKINSON DISEASE (Disorder)

## Interventions

- **DRUG:** LECIG (levodopa, carbidopa, entacapone intestinal gel)
- **DRUG:** Best oral medication

## Key facts

- **NCT ID:** NCT07151378
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-27
- **Primary completion:** 2030-09-22
- **Final completion:** 2030-09-22
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07151378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07151378, "Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07151378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*